Hiring for CA fresher to be part of Global Research & Analytics division
Please go through the Job description and share your CV if interested.
Evaluation of Risk Sensitivities and Attribution outputs.
Migration of PL Explained and Risk Sensitivities between Risk Systems.
Explain Valuation and Risk number breaks for Derivative Products to Trading and Risk team.
Reporting/Documenting classification of breaks and revaluation differences to the concerned team with recommended actions.
Tracking PnL and sensitivities and Risk based PnL explain reports during testing / parallel run period
Liaising with multiple Business Groups including Middle Office, Finance, Quants, IPV and technology teams to address Breaks and take signoffs.
MIS reporting for senior management and relevant stakeholders
CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations. CRISIL's majority shareholder is Standard and Poor(S&P). Standard & Poor's, a part of McGraw Hill Financial is the world's foremost provider of credit ratings.
CRISIL Global Research & Analytics (GR&A) is the largest and top-ranked provider of high end research and analytics services to the world's leading commercial and investment banks, insurance companies, corporations, consulting firms, private equity players and asset management firms. CRISIL GRA operates from research centers in Argentina, China, India and Poland, providing research support across several time zones and in multiple languages to global organizations. It has deep expertise in the areas of equity research, fixed income research (covering global economies, 150 global sectors and over 3000 global companies), valuations, pricing complex derivatives, structured finance, risk management, actuarial analysis and business intelligence.
CRISIL GRA includes Irevna and Pipal Research, firms which were acquired by CRISIL. For more information, please visit www.irevna.com, www.pipalresearch.com